CORT Aug 2024 40.000 call
| Previous close | 1.6500 |
| Open | 1.5500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 40.00 |
| Expiry date | 2024-08-16 |
| Day's range | 1.5500 - 1.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksCorcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ReutersTeva sues Corcept over mifepristone 'monopoly' for rare disorder
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome. The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.
Simply Wall St.Insider-Owned Growth Companies To Watch On US Exchanges In June 2024
As of June 2024, the U.S. stock market exhibits a cautious tone, with investors weighing the implications of recent Treasury auctions and Federal Reserve decisions amidst ongoing political uncertainties in Europe. In such a market environment, growth companies with high insider ownership can be particularly noteworthy as these insiders may have a vested interest in the company's long-term success, potentially aligning their goals closely with those of external shareholders.
